TY - JOUR A2 - Kawauchi, Kiyotaka AU - Nguyen, S. AU - Teh, P. AU - Zhou, J. AU - Chang, E. Y. AU - von Drygalski, A. PY - 2019 DA - 2019/08/28 TI - Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII SP - 9026121 VL - 2019 AB - Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies against Factor VIII (FVIII). It has a high mortality due to bleeding complications. FVIIa-based bypassing agents are the first line of treatment but not always effective. Recombinant porcine (rp) FVIII (Obizur®) was recently approved for rescue treatment but with little evidence-based information regarding efficacy. We report a case of papillary thyroid cancer associated with AHA malignancy that responded to a single dose of rpFVIII after failure to achieve hemostasis with FVIIa-based bypassing products. SN - 2090-6560 UR - https://doi.org/10.1155/2019/9026121 DO - 10.1155/2019/9026121 JF - Case Reports in Hematology PB - Hindawi KW - ER -